Literature DB >> 27010545

Screening Strategies for Nonalcoholic Steatohepatitis in High-Risk Individuals: Trimming Away the Fat.

Raj Vuppalanchi1, Naga Chalasani2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27010545     DOI： 10.1007/s10620-016-4134-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  14 in total

1.  Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study.

Authors:  Raymond Kwok; Kai Chow Choi; Grace Lai-Hung Wong; Yuying Zhang; Henry Lik-Yuen Chan; Andrea On-Yan Luk; Sally She-Ting Shu; Anthony Wing-Hung Chan; Ming-Wai Yeung; Juliana Chung-Ngor Chan; Alice Pik-Shan Kong; Vincent Wai-Sun Wong
Journal:  Gut       Date:  2015-04-14       Impact factor: 23.059

2.  A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease.

Authors:  Giovanni Musso; Roberto Gambino; Maurizio Cassader; Gianfranco Pagano
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

3.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Authors:  Arun J Sanyal; Naga Chalasani; Kris V Kowdley; Arthur McCullough; Anna Mae Diehl; Nathan M Bass; Brent A Neuschwander-Tetri; Joel E Lavine; James Tonascia; Aynur Unalp; Mark Van Natta; Jeanne Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck
Journal:  N Engl J Med       Date:  2010-04-28       Impact factor: 91.245

4.  Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality.

Authors:  Edgar R Miller; Roberto Pastor-Barriuso; Darshan Dalal; Rudolph A Riemersma; Lawrence J Appel; Eliseo Guallar
Journal:  Ann Intern Med       Date:  2004-11-10       Impact factor: 25.391

5.  The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.

Authors:  Leon A Adams; Schuyler Sanderson; Keith D Lindor; Paul Angulo
Journal:  J Hepatol       Date:  2005-01       Impact factor: 25.083

6.  Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.

Authors:  Guillaume Lassailly; Robert Caiazzo; David Buob; Marie Pigeyre; Hélène Verkindt; Julien Labreuche; Violeta Raverdy; Emmanuelle Leteurtre; Sébastien Dharancy; Alexandre Louvet; Monique Romon; Alain Duhamel; François Pattou; Philippe Mathurin
Journal:  Gastroenterology       Date:  2015-04-25       Impact factor: 22.682

7.  Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.

Authors:  Robert J Wong; Ramsey Cheung; Aijaz Ahmed
Journal:  Hepatology       Date:  2014-04-25       Impact factor: 17.425

8.  Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis.

Authors:  Kathleen E Corey; Matthew J Klebanoff; Angela C Tramontano; Raymond T Chung; Chin Hur
Journal:  Dig Dis Sci       Date:  2016-01-29       Impact factor: 3.199

9.  Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.

Authors:  Amy G Shah; Alison Lydecker; Karen Murray; Brent N Tetri; Melissa J Contos; Arun J Sanyal
Journal:  Clin Gastroenterol Hepatol       Date:  2009-06-10       Impact factor: 11.382

10.  Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.

Authors:  Jessica Bazick; Michele Donithan; Brent A Neuschwander-Tetri; David Kleiner; Elizabeth M Brunt; Laura Wilson; Ed Doo; Joel Lavine; James Tonascia; Rohit Loomba
Journal:  Diabetes Care       Date:  2015-04-17       Impact factor: 19.112
View more
  1 in total

Review 1.  Management of nonalcoholic fatty liver disease in the Middle East.

Authors:  Faisal M Sanai; Faisal Abaalkhail; Fuad Hasan; Muhammad Hamed Farooqi; Nawal Al Nahdi; Zobair M Younossi
Journal:  World J Gastroenterol       Date:  2020-07-07       Impact factor: 5.742
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.